Neural RNA Delivery via Epithelial Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating neurological disorders and pathogenic infections of the peripheral and central nervous systems face challenges in delivering therapeutic agents effectively to nerve cells or tissue.
Innovation Solution
The method involves removing or disrupting epithelial cells from a subject's tissue, followed by the application of a recombinant nucleic acid, such as a vector comprising a nucleic acid of interest, to deliver therapeutic agents directly to neural cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional delivery methods are used, then the treatment process is simple, but the delivery efficiency to neural cells is low
Solution Approach 1:
The epithelial cells are removed or disrupted before applying the therapeutic agent, creating a preliminary opening or pathway that facilitates subsequent delivery of the nucleic acid to neural cells. This preliminary action of removing the epithelial barrier enables more efficient penetration and delivery to the target neural tissue.
2Productivity
If epithelial cells are removed to enable delivery, then delivery efficiency improves, but tissue damage increases
Solution Approach 1:
The epithelial removal or disruption is applied locally at the site of neural cell exposure rather than broadly across the entire tissue. This localized approach creates sufficient access for therapeutic delivery while minimizing damage to surrounding healthy tissue and maintaining overall tissue integrity.
3Reliability
If targeted delivery to neural cells is achieved, then treatment effectiveness improves, but the complexity of targeting increases
Solution Approach 1:
The epithelial cells that form a barrier to neural cell access are removed or separated from the underlying neural tissue. This extraction of the interfering epithelial layer allows the therapeutic agent to directly access and target neural cells without the need for complex targeting mechanisms, simplifying the overall approach while maintaining effectiveness.
Data Source
AI summary
Aspects of the application relate to methods and compositions for delivering therapeutic nucleic acids to neural cells or tissue in a subject. Additional aspects of the application relate to therapeutic nucleic acids, for example therapeutic ribozymes, that are useful for inhibiting viral reactivation in a subject.